You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma

Article metrics

Article menu

Download PDFPDF

XML
Immunotherapy biomarkers
Original research
CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma

 

Online download statistics by month:

Online download statistics by month: August 2021 to July 2025

AbstractFullPdf
Aug 202120520588
Sep 202132432692
Oct 202116116123
Nov 202110810816
Dec 202192947
Jan 2022929515
Feb 202265656
Mar 2022808132
Apr 2022979932
May 2022788345
Jun 2022676928
Jul 202211411625
Aug 202217517638
Sep 202216816834
Oct 202217217541
Nov 2022747641
Dec 2022363616
Jan 2023373818
Feb 2023636324
Mar 2023303223
Apr 2023181822
May 2023323217
Jun 202327278
Jul 2023323323
Aug 202318199
Sep 2023252613
Oct 2023313216
Nov 2023252512
Dec 2023414110
Jan 2024343519
Feb 2024262614
Mar 2024565675
Apr 2024454531
May 2024363631
Jun 2024393816
Jul 2024495019
Aug 2024373516
Sep 2024292928
Oct 2024494929
Nov 2024373826
Dec 2024505136
Jan 2025484827
Feb 2025353527
Mar 2025565628
Apr 2025555626
May 2025515132
Jun 2025303015
Jul 2025110
Total325032841269